BACKGROUND: Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19%, 33%, and 47% of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89% vs 70%; P = .35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P = .79). CONCLUSIONS: In this cohort of t-APL patients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APL patients to avoid any risk of anthracycline-induced toxicities.
BACKGROUND:Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19%, 33%, and 47% of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89% vs 70%; P = .35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P = .79). CONCLUSIONS: In this cohort of t-APLpatients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APLpatients to avoid any risk of anthracycline-induced toxicities.
Authors: E Jantunen; K Heinonen; E Mahlamäki; K Penttilä; T Kuittinen; P Lehtonen; M Pyörälä; A Hänninen; T Nousiainen Journal: Leuk Lymphoma Date: 2007-01
Authors: Ashley N Mays; Neil Osheroff; Yuanyuan Xiao; Joseph L Wiemels; Carolyn A Felix; Jo Ann W Byl; Kandeepan Saravanamuttu; Andrew Peniket; Robert Corser; Cherry Chang; Christine Hoyle; Anne N Parker; Syed K Hasan; Francesco Lo-Coco; Ellen Solomon; David Grimwade Journal: Blood Date: 2009-11-02 Impact factor: 22.113
Authors: Anita R Mistry; Carolyn A Felix; Ryan J Whitmarsh; Annabel Mason; Andreas Reiter; Bruno Cassinat; Anne Parry; Christoph Walz; Joseph L Wiemels; Mark R Segal; Lionel Adès; Ian A Blair; Neil Osheroff; Andrew J Peniket; Marina Lafage-Pochitaloff; Nicholas C P Cross; Christine Chomienne; Ellen Solomon; Pierre Fenaux; David Grimwade Journal: N Engl J Med Date: 2005-04-14 Impact factor: 91.245
Authors: Elihu H Estey; Francis J Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan H Faderl; Jorge E Cortes; Hagop M Kantarjian Journal: Blood Date: 2002-06-01 Impact factor: 22.113
Authors: Mette K Andersen; Richard A Larson; Nils Mauritzson; Susanne Schnittger; Suresh C Jhanwar; Jens Pedersen-Bjergaard Journal: Genes Chromosomes Cancer Date: 2002-04 Impact factor: 5.006
Authors: Harold J Olney; Felix Mitelman; Bertil Johansson; Krzysztof Mrózek; Roland Berger; Janet D Rowley Journal: Genes Chromosomes Cancer Date: 2002-04 Impact factor: 5.006
Authors: Vicki A Morrison; Kanti R Rai; Bercedis L Peterson; Jonathan E Kolitz; Laurence Elias; Frederick R Appelbaum; John D Hines; Lois Shepherd; Richard A Larson; Charles A Schiffer Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Alessandro Pulsoni; Livio Pagano; Francesco Lo Coco; Giuseppe Avvisati; Luca Mele; Eros Di Bona; Rosangela Invernizzi; Franco Leoni; Filippo Marmont; Alfonso Mele; Lorella Melillo; Anna Maria Nosari; Enrico Maria Pogliani; Marco Vignetti; Giuseppe Visani; Vittorina Zagonel; Giuseppe Leone; Franco Mandelli Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: M Beaumont; M Sanz; P M Carli; F Maloisel; X Thomas; L Detourmignies; A Guerci; N Gratecos; C Rayon; J San Miguel; J Odriozola; J Y Cahn; F Huguet; A Vekhof; A Stamatoulas; H Dombret; F Capote; J Esteve; A M Stoppa; P Fenaux Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer Journal: Blood Rev Date: 2014-09-30 Impact factor: 8.250
Authors: S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker Journal: Leukemia Date: 2017-03-21 Impact factor: 11.528